What Is the Status of the Dupixent Lawsuit in Maine?

Super Lawyers® 2014–2024(888) 348-2735

Dupixent — CTCL Litigation

The Dupixent Litigation, Explained

Federal cases are consolidated in MDL 3180, most cases are in their earliest stages, and no settlement exists. Here is what is publicly known.

ACTIVE LITIGATION — NO SETTLEMENT. MDL 3180 underway · deadlines vary by state.

Marin & Murphy is not licensed in Maine; details below.

Partners

Stefanie A. Murphy & Matthew T. Marin

Super Lawyers® honorees · members of the American Association for Justice · concentrating in personal injury and mass-tort litigation.

No settlement has been reached in the Dupixent litigation, and most cases are in their earliest stages. Every case must be proven on its own facts. Whether any patient has a claim depends on the facts and the law of their state. The information below covers the litigation itself.

Marin & Murphy Law Firm is not licensed in Maine; details below.

Current Status of the Dupixent CTCL Litigation

Dupixent (dupilumab), a Sanofi and Regeneron prescription biologic prescribed to patients in Maine and nationwide, has been FDA-approved since March 2017 and now carries nine indications, including atopic dermatitis, asthma, and COPD. The order that matters for Maine filings came in June 2026: the Judicial Panel on Multidistrict Litigation centralized the pending federal cases as MDL 3180 in the United States District Court for the District of New Jersey, before Judge Zahid N. Quraishi. The complaints in the consolidated Dupixent lawsuit allege that the drug is associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and that the manufacturers failed to warn patients and doctors. At least 34 identified member cases were on the MDL docket — the same proceeding a case from Maine would join — as of August 25, 2026; the MDL 3180 tracker keeps the current count and its method. For Maine claimants as for all others, no court has ruled on the merits and no settlement exists.

What Is Alleged, and What Has Not Been Established

The allegation — in Maine as anywhere else — is an association, not an adjudicated fact. Published studies report a statistical association between dupilumab and CTCL — an association the study authors themselves note does not establish causation — and the FDA has identified a potential safety signal for CTCL that it is still evaluating. The Dupixent label dispensed in Maine, as everywhere, carries no lymphoma or malignancy warning today. The FDA adverse event reports connected to this question are agency reports, not verified causes, and the courts have decided nothing on the merits — in Maine or anywhere else.

Is Anyone From Maine Already in the Dupixent Litigation?

Possibly, but the public record does not yet let us say so responsibly. All federal Dupixent CTCL cases are consolidated in MDL 3180 in the District of New Jersey, and the MDL’s member-case complaints are mostly not in the free public record; a case’s original filing court also does not establish where the plaintiff lives. This page therefore reports the litigation’s overall posture through the MDL 3180 tracker rather than an unverified Maine figure, and it will describe a Maine resident’s case when a publicly available complaint documents one.

Who Is Included in the Filed Cases?

People in the consolidated cases — a group any qualifying claimant from Maine would join — used Dupixent and received a diagnosis of cutaneous T-cell lymphoma or a related T-cell subtype during or after use. No minimum duration of Dupixent use is required — in Maine or anywhere — and the group includes estate claims, brought under state wrongful-death and survival statutes, for patients who have died. Whether any individual’s circumstances resemble the filed cases is a question of medical records and state law, not of headlines — and for a Maine resident, it is a question for an attorney licensed in Maine.

Maine’s Federal Courts and the Path to MDL 3180

Maine has one federal district court: the United States District Court for the District of Maine. A Dupixent CTCL lawsuit filed there will not proceed on its own: these cases are centralized by the Judicial Panel on Multidistrict Litigation as MDL 3180 before Judge Zahid N. Quraishi in the United States District Court for the District of New Jersey, so a Maine case is transferred to the MDL for coordinated pretrial proceedings — or, where the MDL court’s case-management orders permit, filed in the District of New Jersey directly. The destination is the same consolidated proceeding either way; a claim from Maine stays an individual claim, because an MDL is not a class action.

Filing Deadlines Under Maine Law

Maine’s general statute of limitations for personal-injury claims is six years under 14 M.R.S. § 752. Maine does not recognize a general discovery rule for personal-injury or product-liability claims: accrual occurs when the wrongful act is coupled with injury, and Maine’s narrow discovery exceptions (legal malpractice, foreign-object and negligent-diagnosis medical malpractice, asbestosis) do not extend to prescription-product claims. How a limitations period applies to any specific CTCL diagnosis depends on the dates in the medical records, the legal theory pleaded, and Maine tolling and accrual doctrine. An attorney licensed in Maine can evaluate whether a claim is timely.

A wrongful-death claim carries a three-year period measured from the date of death (18-C M.R.S. § 2-807(2)), brought by the personal representative.

How Common Is CTCL in Maine?

Maine is home to about 1.4 million people (U.S. Census Bureau, 2024 estimate). Cutaneous T-cell lymphoma is rare — roughly 8.55 new cases per million person-years (SEER) — which works out to on the order of 12 new CTCL diagnoses across Maine in a typical year. Because the disease is so rare, no statistic here answers an individual question; in Maine, a single claim turns on medical records read against state law.

About Marin & Murphy Law Firm and Maine

Marin & Murphy Law Firm is a personal-injury and mass-tort law firm; its attorneys’ individual admissions are listed at the bottom of this page, and this page is published as litigation information. Marin & Murphy Law Firm is not licensed in Maine. The firm does not accept Maine legal matters; inquiries from Maine residents are referred to attorneys licensed in Maine. Some matters may be referred to other lawyers. An attorney licensed in Maine can evaluate whether a claim is timely and how Maine law applies to a particular diagnosis.

Maine Dupixent Litigation FAQs